Twin Capital Management Inc. Makes New $812,000 Investment in Biogen Inc. $BIIB

Twin Capital Management Inc. purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,430 shares of the biotechnology company’s stock, valued at approximately $812,000.

Several other institutional investors and hedge funds have also recently modified their holdings of BIIB. Norges Bank acquired a new stake in Biogen during the fourth quarter worth about $464,408,000. Boston Partners acquired a new position in Biogen in the 4th quarter valued at about $302,815,000. Fred Alger Management LLC boosted its holdings in Biogen by 39,074.8% in the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares during the last quarter. Employees Provident Fund Board purchased a new stake in shares of Biogen in the 4th quarter valued at approximately $123,931,000. Finally, Orion Porfolio Solutions LLC grew its stake in shares of Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Citigroup upped their price objective on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Sanford C. Bernstein lowered their price objective on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Zacks Research cut Biogen from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Mizuho reduced their target price on Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $220.04.

Biogen Stock Performance

NASDAQ:BIIB opened at $208.92 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock has a market capitalization of $30.84 billion, a P/E ratio of 22.42 and a beta of 0.16. The company has a 50 day moving average price of $199.18 and a 200 day moving average price of $188.88. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $219.72.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the company earned $3.02 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts forecast that Biogen Inc. will post 13.5 EPS for the current year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Synapticure launched a new virtual ataxia care program with Biogen support, highlighting continued investment in Biogen’s neurology franchise and potentially broadening patient access. Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
• Positive Sentiment: Biogen appointed Michael J. Parini as Chief Legal Officer, a seasoned biopharma leader whose compliance and strategic experience may support execution and governance. Biogen Appoints Michael J. Parini as Chief Legal Officer
• Neutral Sentiment: Analysts offered fresh commentary on Biogen, but the headline did not include a clear new rating or target change, so the stock impact appears limited. Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Biogen (BIIB)
• Negative Sentiment: Recent Alzheimer’s-related data on diranersen and tau-targeting ASO programs raised questions about dosing and trial progress, which weighed on sentiment toward Biogen’s pipeline. Biogen shares slide as diranersen data raise dosing question
• Negative Sentiment: Investors reacted negatively to detailed diranersen Alzheimer’s study data, as the results reinforced concerns about a prior phase II setback despite plans to move ahead. Biogen Shares Decline After Detailed Diranersen Alzheimer’s Study Data

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.